Clinical characteristics and sick leave associated with infectious mononucleosis in a real-world setting in Germany.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
17
03
2021
accepted:
27
07
2021
pubmed:
1
8
2021
medline:
22
9
2021
entrez:
31
7
2021
Statut:
ppublish
Résumé
Infectious mononucleosis (IM), mainly caused by the Epstein-Barr virus, can result in prolonged symptoms. The objective of this study was to look at the length of sick leave, diagnosis of IM, treatment and comorbidities in a real-world setting in Germany. This retrospective, cross-sectional study used electronic medical record data from office-based practices in Germany and included patients with an initial confirmed diagnosis of IM between the 1 January 1 2016 and December 31 2018. Patients of working age (18-65 years) with statutory health insurance were included in order to look at the working population who would need a sick note for their employers in case of illness. Epstein-Barr virus was the most common cause of IM in this population of 1,596 patients with an average age of 32 years. The majority of patients were women in all cohorts (~60%). Although CFS, myocarditis and thrombocytopenia were not recorded frequently around the index date, the occurrence did increase during the follow-up period. Around half of patients received antibiotics. About 62% of all patients were on sick leave for an average of 20 calendar days around the time of their IM diagnosis. Only 1% were still on sick leave after 6 months. A small percentage of patients remained on continuous sick leave after 6 months, suggesting that the long-term effect of IM on the ability to work was minor in our cohort. However, patients could still be experiencing symptoms that influence their quality of life.
Sections du résumé
BACKGROUND
BACKGROUND
Infectious mononucleosis (IM), mainly caused by the Epstein-Barr virus, can result in prolonged symptoms. The objective of this study was to look at the length of sick leave, diagnosis of IM, treatment and comorbidities in a real-world setting in Germany.
METHODS
METHODS
This retrospective, cross-sectional study used electronic medical record data from office-based practices in Germany and included patients with an initial confirmed diagnosis of IM between the 1 January 1 2016 and December 31 2018. Patients of working age (18-65 years) with statutory health insurance were included in order to look at the working population who would need a sick note for their employers in case of illness.
RESULTS
RESULTS
Epstein-Barr virus was the most common cause of IM in this population of 1,596 patients with an average age of 32 years. The majority of patients were women in all cohorts (~60%). Although CFS, myocarditis and thrombocytopenia were not recorded frequently around the index date, the occurrence did increase during the follow-up period. Around half of patients received antibiotics. About 62% of all patients were on sick leave for an average of 20 calendar days around the time of their IM diagnosis. Only 1% were still on sick leave after 6 months.
CONCLUSIONS
CONCLUSIONS
A small percentage of patients remained on continuous sick leave after 6 months, suggesting that the long-term effect of IM on the ability to work was minor in our cohort. However, patients could still be experiencing symptoms that influence their quality of life.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14690Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Lennon P, Crotty M, Fenton JE. Infectious mononucleosis. BMJ. 2015;350:h1825.
Kuri A, Jacobs BM, Vickaryous N, et al. Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom. BMC Public Health. 2020;20:912.
Balfour HH, Dunmire SK, Hogquist KA. Infectious mononucleosis. Clin Transl Immunol. 2015;4:e33.
Balfour HH Jr, Odumade OA, Schmeling DO, et al. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr Virus infection in university students. J Infect Dis. 2013;207:80-88.
Candy B, Chalder T, Cleare AJ, Wessely S, White PD, Hotopf M. Recovery from infectious mononucleosis: a case for more than symptomatic therapy? A systematic review. Br J Gen Pract J R Coll Gen Pract. 2002;52:844-851.
Buchwald DS, Rea TD, Katon WJ, Russo JE, Ashley RL. Acute infectious mononucleosis: characteristics of patients who report failure to recover. Am J Med. 2000;109:531-537.
Koopmans PC, Bakhtali R, Katan AA, Groothoff JW, Roelen CA. Return to work following sickness absence due to infectious mononucleosis. Occup Med Oxf Engl. 2010;60:249-254.
Rea TD, Russo JE, Katon W, Ashley RL, Buchwald DS. Prospective study of the natural history of infectious mononucleosis caused by Epstein-Barr Virus. J Am Board Fam Pract. 2001;14:234-242.
Katz BZ, Shiraishi Y, Mears CJ, Binns HJ, Taylor R. Chronic fatigue syndrome following infectious mononucleosis in adolescents: a prospective cohort study. Pediatrics. 2009;124:189-193.
Petersen I, Thomas JM, Hamilton WT, White PD. Risk and predictors of fatigue after infectious mononucleosis in a large primary-care cohort. QJM Mon J Assoc Phys. 2006;99:49-55.
Nyland M, Naess H, Birkeland JS, Nyland H. Longitudinal follow-up of employment status in patients with chronic fatigue syndrome after mononucleosis. BMJ Open. 2014;4:e005798.
Ebell MH. Epstein-Barr virus infectious mononucleosis. Am Fam Phys. 2004;70:1279-1287.
Grotto I, Mimouni D, Huerta M, et al. Clinical and laboratory presentation of EBV positive infectious mononucleosis in young adults. Epidemiol Infect. 2003;131:683-689.
Rathmann W, Bongaerts B, Carius HJ, Kruppert S, Kostev K. Basic characteristics and representativeness of the german disease analyzer database. Int J Clin Pharmacol Ther. 2018;56:459-466.
Jason LA, Katz BZ, Shiraishi Y, Mears CJ, Im Y, Taylor RR. Predictors of post-infectious chronic fatigue syndrome in adolescents. Health Psychol Behav Med. 2014;2:41-51.